08:53:37 EDT Sun 23 Sep 2018
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
SQI Diagnostics Inc
Symbol C : SQD
Shares Issued 134,936,136
Close 2018-06-13 C$ 0.17
Recent Sedar Documents

SQI Diagnostics appoints Zwisler as director

2018-06-13 11:34 ET - News Release

Mr. Clive Beddoe reports

SQI APPOINTS ERIC ZWISLER, A WORLD LEADER IN THE HEALTHCARE MARKET, TO ITS BOARD OF DIRECTORS

SQI Diagnostics Inc. has appointed Eric Zwisler to its board of directors.

Clive Beddoe, SQI's chair, said: "To have someone of Eric Zwisler's calibre on the SQI board is an endorsement of the technical and commercial success of SQI, and marks a turning point in the growth and leadership of the company from a research-driven North American enterprise to a revenue-driven commercial enterprise. His appointment sends a signal from the international health care community that SQI has the technology, the track record and the momentum to achieve significant adoption with both big pharma and big diagnostics customers."

Mr. Zwisler stated: "SQI has an impressive history of diagnostic technology development and a strong management team. At this important time in SQI's development and commercialization, I'm looking forward to working with the board and management to further drive SQI's business forward."

Mr. Zwisler has been a senior executive in the health care business for over 30 years. Most recently, he was chairman of Cardinal Health China, a subsidiary of Cardinal Health (a U.S. Fortune 15 health care company). In addition to his role at Cardinal Health, for the last several years Mr. Zwisler has also been active in health care investments, other board roles and education.

He spent many of the last 30 years in Asia, particularly China, where he won major awards from the Chinese government for his business acumen and commitment to the development of the health care industry in the world's fastest-growing market. Last year, he played a key role in the sale of Cardinal Health China to a local company for $1.2-billion and participated in the deal process by leading a management buyout proposal.

Mr. Zwisler is an internationalist who has worked extensively with businesses and investors from the United States, Europe, Japan and South America. He is a proven leader of large organizations and is operationally adept in strategic, operational, commercial and financial matters. He also has extensive board experience in health care services, immunology research and development. He is well versed in capital structure issues and strategy, financial controls and management, as well as compliance matters.

In addition, Mr. Zwisler is a director of the La Jolla Institute for Allergy and Immunology, one of the world's top five biomedical research institutes focused on understanding the immune response to infectious agents and cancers. For 12 years, Mr. Zwisler was a board member of the International Federation of Pharmaceutical Wholesalers, the international trade organization of pharmaceutical distributors, serving as chair of that body from 2012 to 2014.

Mr. Zwisler is a keen China observer and a frequent commentator on political, economic and health care industry trends.

As compensation for his role on the board, Mr. Zwisler has been granted 700,000 stock options. The grant is effective June 11, 2018, and the options have an exercise price of 18 cents. Pursuant to the company's stock option plan, these options have a term of five years and vest over a three-year period.

About SQI Diagnostics Inc.

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.